7 recruiting, 4 not yet recruiting, 3 completed, 3 unknown. 23 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 23 | Recruiting 7, Not yet recruiting 4, Completed 3, Unknown 3, Terminated 2, Withdrawn 2, Active not recruiting 1, Suspended 1 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases RD06-05 CAR-T Cell Injection - SLE - Systemic Lupus Erythematosus, Systemic Sclerosis | Early Phase 1 | Not yet recruiting | Nanjing Bioheng Biotech Co., Ltd. | 30 | 2026-09-01 | 2026-07-16 |
| Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-04-01 | 2026-04-02 |
| MTS109 in Patients With Refractory Autoimmune Diseases MTS109 - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies | Early Phase 1 | Recruiting | Shanghai Changzheng Hospital | 15 | 2026-03-24 | 2026-06-30 |
| Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases anti-CD19/BCMA U CAR T cells - Autoimmune Diseases, Systemic Lupus Erythematosus | Early Phase 1 | Recruiting | Changhai Hospital | 60 | 2026-02-20 | 2026-02-25 |
| Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases BCT301 - System Lupus Erythematosus, Systemic Sclerosis (SSc) | Early Phase 1 | Recruiting | Peking University Third Hospital | 10 | 2025-12-11 | 2026-09-23 |
| the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases V001-BCMA - Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases | Early Phase 1 | Active not recruiting | Tongji Hospital | 45 | 2025-11-04 | 2026-09-17 |
| A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. RD06-05 CART Cell Injection - SLE, LN | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 96 | 2025-07-24 | 2026-08-03 |
| A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases LCAR-AIO T cells - Relapsed/Refractory Autoimmune Diseases | Early Phase 1 | Withdrawn | Nanjing Legend Biotech Co. | 2025-06-17 | 2025-07-08 | |
| Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV RD06-04 Cell Injection Infusion - Idiopathic Inflammatory Myopathies, ANCA-Associated Vasculitis | Early Phase 1 | Not yet recruiting | Peking University People's Hospital | 12 | 2025-06-14 | 2025-05-22 |
| Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases RD06-05 CART Cell Injection - SLE, Systemic Sclerosis | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 18 | 2025-01-03 | 2026-02-02 |
| Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases CD19 or CD19-BCMA CAR-T - SLE (Systemic Lupus), Systemic Sclerosis | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 20 | 2024-09-14 | 2026-03-06 |
| Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases RD06-04 CART Cell Injection - Systemic Lupus Erythematosus, Systemic Sclerosis | Early Phase 1 | Suspended | Nanjing Bioheng Biotech Co., Ltd. | 12 | 2024-09-13 | 2026-02-03 |
| A Study of RD06-04 in Patients With Active Autoimmune Diseases RD06-04 cell infusion - SLE, Sclerosis | Early Phase 1 | Withdrawn | Nanjing Bioheng Biotech Co., Ltd. | 2024-08-31 | 2026-02-03 | |
| IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy IMPT-514 CART Cell Injection - Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV) | Early Phase 1 | Terminated | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 3 | 2024-06-13 | 2026-01-28 |
| The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases anti-CD19-CAR-T cells - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | Early Phase 1 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 9 | 2024-05-27 | 2024-05-17 |
| Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Meperizumab injection, NUCALA® - Granulomatosis With Polyangiitis, Hemophagocytic Syndrome | Early Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 | 2022-06-01 | 2022-04-29 |
| A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis CD19/BCMA CAR T-cells - POEMS Syndrome, Amyloidosis | Early Phase 1 | Unknown | Zhejiang University | 75 | 2021-10-08 | 2022-03-03 |
| Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease Atorvastatin and anakinra - Kawasaki Disease | Early Phase 1 | Completed | University of California, San Diego | 5 | 2019-06-22 | 2026-02-25 |
| Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome HPC cell infusion - Churg-Strauss Syndrome | Early Phase 1 | Terminated | Mounzer Agha | 1 | 2016-04-01 | 2017-08-01 |
Showing 20 of 23. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (16) · Lupus Erythematosus, Systemic (11) · Scleroderma, Systemic (11) · Myositis (9) · Autoimmune Diseases (7) · Sjogren's Syndrome (6) · Glomerulonephritis, IGA (3) · Antiphospholipid Syndrome (2) · Arthritis, Rheumatoid (2) · Recurrence (2) · Amyloidosis (1) · Anemia, Hemolytic, Autoimmune (1) · Anti-Glomerular Basement Membrane Disease (1) · Behcet Syndrome (1) · Churg-Strauss Syndrome (1)
Cardiovascular Diseases (23) · Vascular Diseases (23) · Skin Diseases (22) · Skin Diseases, Vascular (22) · Skin and Connective Tissue Diseases (22) · Immune System Diseases (21) · Systemic Vasculitis (18) · Autoimmune Diseases (14) · Connective Tissue Diseases (13) · Musculoskeletal Diseases (12) · Nervous System Diseases (12) · Neuromuscular Diseases (10) · Muscular Diseases (9) · Arthritis (8)
Abatacept (1) · Antigens, CD19 (1) · Atorvastatin (1) · Interleukin 1 Receptor Antagonist Protein (1) · Magnetic Resonance Spectroscopy (1) · mepolizumab (1)
Nanjing Bioheng Biotech Co., Ltd. (6) · Changhai Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Grit Biotechnology (1) · Jonsson Comprehensive Cancer Center (1) · Mounzer Agha (1) · NYU Langone Health (1) · Nanjing Legend Biotech Co. (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · Shaare Zedek Medical Center (1) · Shanghai Changzheng Hospital (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · The Children's Hospital of Zhejiang University School of Medicine (1)
China (18) · United States (3) · Israel (1)
Adriana Tremoulet, MD (1) · David Shemesh, MD (1) · He Huang, PhD (1) · LI Sun, Master's (1) · Martin Allen-Auerbach (1) · Mounzer Agha, MD (1) · Qiong Fu, Doctor (1)
R01HL140898 (1)